The starting normal seed contains 22 unique GO assertions and two alternative products for human Q7Z3E5. The raw UniProt record, GOA file, four normal publication caches and seeded review were preserved before research. The review remains INITIALIZED with all decisions PENDING during prospective consultation. One configured Falcon deep-research attempt with the configured fallback failed after 4.155 seconds with connection/timeout indicators and no report; these are manual research notes, not a generated provider report. No verified seeded input was fetched again.
ARMC9 is an 818-residue LisH/armadillo-repeat protein that organizes a ciliary protein interaction network. Human cell localization places it at the basal body and daughter centriole; mammalian ciliary localization is dynamic, with Hedgehog-dependent tip enrichment in the mouse cell systems studied. Its partners include TOGARAM1, CSPP1 and CCDC66. The strongest mechanistic evidence now distinguishes its structural contribution to a complex from autonomous microtubule binding or polymerase activity. Biallelic variants cause Joubert syndrome 30, with the characteristic hindbrain malformation and variable neurological, ocular and other ciliopathy features. No enzyme activity is inferred from altered tubulin modifications, mitochondrial phenotypes, or association with an enzyme/assembly factor.
PMID:28625504, Mutations in ARMC9, which Encodes a Basal Body Protein, Cause Joubert Syndrome in Humans and Ciliopathy Phenotypes in Zebrafish. The complete normal cached abstract and original PubMed Figure 3 caption were read. Endogenous ARMC9 staining in serum-starved human hTERT-RPE1 cells identifies both the ciliary basal body and daughter centriole, using RPGRIP1L, acetylated tubulin and gamma-tubulin landmarks. The caption supports the two human localization assertions directly. The study also reports affected human families and zebrafish loss-of-function phenotypes; human clinical genetics and fish perturbation are kept distinct. The cache is abstract-only, and complete original Methods/antibody validation and all supplemental data have not been inspected. Original PubMed record and figure captions.
PMID:32453716, Dysfunction of the ciliary ARMC9/TOGARAM1 protein module causes Joubert syndrome. The complete cached abstract, original Results on interaction mapping and Figure 1, patient fibroblast tubulin modifications/cold sensitivity/resorption, relevant Discussion, and the first portion of the original Supplemental Methods were read. Full-length ARMC9 and fragments were screened against bovine and human retinal libraries. Follow-up Y2H and tagged co-IP establish ARMC9 self-association and interactions with TOGARAM1, CCDC66 and CSPP1. CEP104 is supported by co-IP rather than the binary Y2H result. TOGARAM1 binding maps to its N-terminal region containing TOG1/TOG2 and to an ARMC9 region containing its coiled coil and ARM repeats; self-association maps to the N-terminal 350 residues. The supplemental cloning section explicitly names human reference cDNAs, including ARMC9 NM_025139.2, rather than requiring reagent-species inference from the host. Supplemental cloning, human cell culture and PalmMyr procedures were inspected; later TAP/Y2H/co-IP protocol details and the full supplemental target tables were not exhaustively read. PalmMyr is forced membrane targeting, not physiological plasma membrane evidence. Patient fibroblasts have reduced ciliary tubulin acetylation/polyglutamylation, greater cold sensitivity and faster serum-induced ciliary resorption; these are consequences of loss of the protein module, not evidence that ARMC9 performs the modifying chemistry. Original article and Supplemental Methods. The canonical cache remains abstract-only despite this separate external body read.
PMID:38949024, Primary cilia formation requires the Leigh syndrome-associated mitochondrial protein NDUFAF2. The complete normal abstract, targeted full-text interaction, patient-cell rescue and Discussion sections, and the plasmid, cell-culture, PLA and CRISPR Methods were read. Human NDUFAF2, ARMC9 and TOGARAM1 constructs are specified by vendor accession. Tagged 293T co-IP maps NDUFAF2 association to the ARMC9 coiled-coil/ARM-containing region; PLA reports proximity near basal bodies and mitochondria, not a purified binary interface. Patient ARMC9-deficient fibroblasts show short cilia and mitochondrial defects; NDUFAF2 overexpression can rescue several readouts. The authors leave the coordinating mechanism unresolved. The separate GOA TOGARAM1 pair is not yet closed at the source-local experiment level: TOGARAM1 appears in the Introduction and plasmid Methods, but the figure legend does not name that pair, and the actual Figure 3 blot labels or supplemental pair assay were not successfully inspected. The figure image URL was found, but native image retrieval failed DNS without bytes. Independent 2020/2025 TOGARAM1 evidence establishes biological plausibility without verifying this particular 2024 assertion. No wrong-paper claim follows from this access gap. Original article and Figure 3 legend. This normal cache contains full XML text.
PMID:19056867, Large-scale proteomics and phosphoproteomics of urinary exosomes. The complete normal abstract was read. This is a human urinary-exosome proteomics study, but an ARMC9-specific target identification, peptide assignment and fraction/vesicle interpretation have not been independently inspected. Retaining uncertainty about the exact HDA assertion neither rejects the experiment nor treats lack of a signal peptide as disproof. The normal cache is abstract-only. Original PubMed record.
PMID:29459677, A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Official PubMed identity, the complete publisher abstract, indexed original PMC ARMC9 Results and Figure 5 caption were read. In mouse NIH-3T3/IMCD3 systems, Armc9 loss affects cilium length/tubulin modifications and attenuates GLI2/GLI3 tip accumulation. Tagged ARMC9 moves from a proximal ciliary region toward the tip after Hedgehog stimulation and later returns; vismodegib blocks redistribution. SMO accumulation is not the ARMC9-specific defect reported there. GLI transport/retention is a mechanistic suggestion, not a demonstrated motor, direct GLI-binding or enzyme activity. The complete plasmid Methods/sequence provenance have not been read; mouse host identity does not prove tagged construct species. The existing human ISS/IBA transfer remains explicitly ortholog based. Original PubMed, PMC article and publisher.
PMID:39856351, A network of interacting ciliary tip proteins with opposing activities imparts slow and processive microtubule growth. The complete primary abstract, ARMC9/TOGARAM1/CSPP1 Results and Figure 5 legend, complex-composition perturbation Results, relevant Discussion, DNA-construct, co-IP, purification/SEC/MS and reconstitution Methods, and selected Extended Data 1/4 legends were read externally. The Methods explicitly use human module members except mouse TOGARAM1; proteins were expressed/purified from HEK293T cells, and the reconstitution uses porcine brain tubulin. ARMC9 forms dimers and binds TOGARAM1 and CSPP1 through different regions. It does not independently bind microtubules or alter their dynamics under the tested conditions. TOGARAM1 or CSPP1 recruits it, and it enhances partner-dependent rescue/pausing. Combined module proteins form plus-end structures and support very slow processive growth. Changing component ratios matters; removal of ARMC9 alone does not abolish the entire complex behavior. The experiments support a structural organizing contribution rather than a claim that ARMC9 alone is necessary/sufficient for all module activity. The older weak CEP104 co-IP was not reproduced in this study; that discrepancy will remain visible rather than erasing the earlier observation. Original PubMed, publisher article and PMC article. Full supplemental tables and every figure pixel were not inspected.
The two additional papers, 29459677 and 39856351, are absent from the normal canonical cache. A single normal two-ID batch was interrupted at 45.040 seconds, exit -15, with zero output cache files. This was one interrupted batch, not two completed individual failures. The exact receipt and independent primary-identity/abstract consultation are preserved under tmp/ARMC9-initial. They are proposed for the finite Source44 recovery; no retry was made. External reading does not change canonical availability flags.
The existing cilium-assembly and basal-body/centriole assertions are consistent with the human localization, patient-cell phenotypes and conserved ciliary role. Human evidence supports the truth of these assertions independently of a full reconstruction of the PAINT ancestral node. The target appearing in the IBA donor list is expected, not circular; no donor-count argument is used. No exact PTN000382362 topology has been independently reconstructed. The ciliary-tip location is retained with its conditional mouse-cell/ortholog-transfer scope. The Smoothened-pathway process is retained as a downstream signaling context rather than expanded to an intrinsic signaling enzyme or a new BP.
Positive binding assays remain valid under the user's ActionEnum. A true interaction does not become REMOVE solely because GO:0005515 is broad. Source-local uncertainty is retained when the precise experiment is unadjudicated. For the 2020 TOGARAM1 row, whether its two-TOG-domain-region mapping justifies GO:0019904 is explicitly submitted for independent consultation; the newer isolated TOG2 result will not be silently attributed to the older IPI row.
One candidate NEW molecular function is GO:0140378 protein complex scaffold activity, anchored to the 2025 reconstitution and distinct binding regions, with the 2020 module study as corroboration. The official definition is a structural activity of an integral component holding a protein complex together, under structural molecule activity. GO:0030674's own comment directs protein-complex scaffolds to GO:0140378. This is a proposed mechanistic activity, not a new process inferred merely from knockout/rescue. A tentative single core would connect that activity to existing cilium assembly and basal-body/ciliary-tip locations, while retaining explicit uncertainty about transfer of the detailed tip reconstitution mechanism to the basal-body pool. No new BP or molecular activity of tubulin modification, mitochondrial metabolism, microtubule binding/polymerization, or motor transport is proposed. Existing identical-protein binding records the oligomerization component; the core need not list it redundantly as a second independent activity.
Official terms actually inspected: GO:0140378, GO:0030674 and GO:0019904. The local GO-CAM index search found no Q7Z3E5/ARMC9 hit. Neither this absence nor absence of a NEW process annotation is treated as a curation gap. Both supplied alternative-product objects will be retained; tagged fragments or canonical constructs do not establish isoform-exclusive function.
Open mechanistic questions include the physiological composition and stoichiometry of the ARMC9 module at basal bodies versus ciliary tips, how NDUFAF2 association connects mitochondrial state to ciliary structure, and which assay conditions explain the differing CEP104 co-IP observations.
The initial research statements above describe the pre-authorship state. The independent all22 consultation supported 14 ACCEPT, six KEEP_AS_NON_CORE and two UNDECIDED decisions; these are now authored with all source objects and both alternative products preserved. The 2020 two-domain TOGARAM1 mapping remains non-core, and the unresolved 2024 pair remains uncertain. The organizing network is flexible rather than a fixed-stoichiometry assembly, and ARMC9 has no autonomous microtubule-binding activity in the tested reconstitution. The agreed GO:0140378 molecular-function proposal and detailed source attachments will be added after the two Source44 normal records are recovered and inspected. No new biological process is proposed. This draft is not COMPLETE.
The earlier pending-source statements are historical. Both requested normal records were recovered as complete XML and imported as exact archive bytes after the separate validator and identity checks. Existing source caches and raw inputs remain unchanged. The current review contains all 22 original assertions (14 ACCEPT, six KEEP_AS_NON_CORE and two UNDECIDED), plus one NEW molecular function; no new biological process is proposed.
For PMID:29459677, the actual ARMC9 Results, relevant Discussion, cell culture, general cloning, stable-cell, reporter/localization and fluorescence-quantification Methods were read. The experiment uses mouse NIH-3T3 and IMCD3 cells. General cloning allows mouse cDNA or commercial sources, leaving the particular tagged ARMC9 sequence origin unresolved. ARMC9-FLAG accumulates toward the tip after Hedgehog stimulation and later returns; mutant cells have shorter cilia and altered tubulin-modification levels. GLI2/GLI3 accumulation is affected without the same SMO effect. These data support the existing ortholog-transfer/contextual annotations, not direct motor or SMO-binding activity. The earlier external Figure5 caption read remains separate from this actual main-body read. [PMID:29459677, "Armc9 mutant NIH-3T3 cells exhibited reduced ciliary accumulation of GLI2 and GLI3 (but not SMO) upon pathway activation"]
For PMID:39856351, actual ARMC9/domain/recruitment and module Results, Figure5–7 captions, relevant Discussion, DNA constructs, co-IP, purification/SEC/MS and microtubule-reconstitution Methods were read. Human ARMC9 was expressed in HEK293T, with mouse TOGARAM1 and porcine brain tubulin in the mixed reconstitution. Distinct ARMC9 surfaces bind TOGARAM1 and CSPP1; partner recruitment and modest dynamic effects support GO:0140378 protein complex scaffold activity. This supplies a structural contribution, rather than inferring a process solely from perturbation. It is not autonomous microtubule binding or tubulin-polymerase activity. Single-component omissions, double ARMC9/CCDC66 omission and component-ratio changes support a flexible, partly redundant network, not an obligatory stoichiometric complex. [PMID:39856351, "ARMC9 can bind to both proteins through two distinct domains and mildly enhance their effects on MT dynamics"]
The 2025 weak CEP104 co-IP nonreplication is retained beside the older positive record, without declaring the original experiment incorrect. Older generic IPI assertions do not inherit newer fine-mapping assays. The uninspected 2024 TOGARAM1 blot and urinary-exosome target evidence remain UNDECIDED. Complete supplements, raw data and figure pixels were not exhaustively inspected. The independent prospective consultation approved this bounded new scaffold assertion; final authored consultation and validation are recorded separately.
The published review and history remain the historical baseline. This follow-up retains all 22 original annotation objects and changes one original decision: the 2020 TOGARAM1 interaction is refined to GO:0019904 protein domain specific binding. The single author-added 2025 assertion is conservatively represented as GO:0030674 protein-macromolecule adaptor activity; this replaces the earlier scaffold term and does not add a second NEW annotation or a process annotation.
The original 2020 Figures 1 and 3 map ARMC9 binding to the TOGARAM1 N-terminal TOG1/TOG2 fragment; R368W and L375P in TOG2 disrupt association, whereas R1311C in TOG3 retains it. These experiments support domain-specific recognition without proving an isolated TOG2 interface.
The external original 2020 Results and Figures 1 and 3 were inspected for that conclusion. The normal PMID:32453716 cache remains abstract-only. Human reference constructs, retinal yeast two-hybrid screening, tagged co-immunoprecipitation and forced PalmMyr targeting have their distinct experimental scopes. The newer 2025 TOG2 fine mapping is independent evidence and is not attributed to the 2020 experiment.
The actual PMID:39856351 text reports distinct ARMC9 regions for TOGARAM1 and CSPP1 interactions, partner-dependent recruitment and modulation of microtubule dynamics. The reconstitution combines human ARMC9 with mouse TOGARAM1 and porcine tubulin. H-region-dependent dimerization is demonstrated, but TOGARAM1 binding maps independently of H; dimerization is not established as necessary for every bridge. Whole-module cryo-electron tomography does not assign ARMC9 an integral structural position. The authors' scaffold interpretation remains plausible. Variable stoichiometry and the mild single-deletion effect do not independently disprove scaffold activity. FRAP measures CEP104 turnover, not ARMC9 or turnover of the whole assembly.
Current GO:0030674, GO:0140378 and GO:0019904 definitions and relevant comments were inspected. Coordinated recruitment provides positive support for the adaptor assertion. Nonstoichiometry is a limitation, not its positive evidence. A formal location for this specific activity is omitted because its spatial assignment in cells remains unresolved. GO location edges do not require exclusivity. All accepted protein-localization annotations remain, including human basal-body/daughter-centriole and conditional mouse-cell tip observations; those distributions alone do not assign the same activity to every site.
The 2024 human TOGARAM1 construct is documented in Methods, but its pair-labelled blot or supplementary interaction assay remains uninspected. The accessible Figure 3 legend does not resolve those labels; image and PDF access routes did not provide the needed panel. Independent earlier and later interactions establish biological plausibility without verifying this particular IPI experiment. Its decision remains UNDECIDED. The urinary-exosome target identification also remains unresolved.
The explicit user ActionEnum permits KEEP_AS_NON_CORE for true interactions and defines REMOVE by likely biological error. It takes precedence over the skill's generic-binding removal default. The positive CCDC66, CEP104, CSPP1 and NDUFAF2 associations therefore remain non-core where their own source does not justify a more specific activity. The CEP104 discrepancy is retained. This policy choice is documented here rather than repeated in each biological reason.
Independent prospective consultation agreed with these changes and the stated construct, domain and location limits. Raw source files, all six normal publication caches and the original history are unchanged.
The review of PR #3371 at c097efb09 correctly identifies the repository default: an uninformative generic binding annotation can be excluded even when its reported interaction is real. That informational-exclusion criterion is distinct from concluding that the experimental evidence is false. The earlier notes should not be read as saying that the default policy requires biological falsity or that these touched annotations qualify for a legacy exception.
This task explicitly directs that generic binding not be removed solely for informativeness, while preserving uncertainty when the relevant experiment cannot be adjudicated. The retained decisions are a scoped application of those task instructions. They are not a claim of compliance with the default generic-binding policy, a global policy revision, or a reason to silence its advisory warnings.
The four retained source-specific associations concern CCDC66, CEP104, CSPP1 and NDUFAF2. The CEP104 nonreplication remains explicit, and NDUFAF2 association does not assign mitochondrial respiratory chemistry to ARMC9. The separately supported 2025 adaptor assertion remains a single NEW annotation; its reconstitution and recruitment evidence is not described as having been measured by every older IPI source. The 2020 TOGARAM1 domain-specific refinement is preserved. No original assertion acquires a new replacement solely to resolve the policy disagreement. The uninspected 2024 TOGARAM1 target assay and urinary-exosome identification remain UNDECIDED.
This addendum changes only the explanation of the decision. It adds no primary-source reading, assay verification, quotation, annotation or core function. All current annotation decisions, products, evidence limitations and source objects remain unchanged.